Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
- Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
- This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
- According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
- "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.